TP53 and myeloid neoplasm: Moreover, several of these cases exhibit high-risk cytogenetic and molecular abnormalities as commonly associated with therapy-related myeloid neoplasms, such as monosomy 7, TP53, or RUNX1 mutations [40,44,108].